Therapeutic efficacy of valsartan accompanied with metoprolol in the patients with congestive heart failure
Jinlin Su
Abstract
Jinlin Su
Abstract
Objective:To evaluate the therapeutic efficacy of valsartan accompanied with metoprolol in the patients with congestive heart failure(CHF).Methods: 96 patients with CHF were randomly divided into group A ( n =46) who had taken conventional treatment of digitalis and diuretics and group B ( n =50) who were given valsartan (40 to 160 mg·d -1 ) and metoprolol (12.5 to 100 mg·d -1 ) on the conventional therapy.The therapeutic period was 6 months. Results: After treatment,cardiac function (NYHA) improved; blood pressure,heart rate,cardiothoracic ratio,left ventricular diastolic ending diameter (LVDd) and left aurial diameter (LAd) all decreased; left ventricular ejectional fraction (LVEF) increased significantly( P 0.05 ) in group B comparing with those in group A. There were few side effects and patients' tolerance was perfect in Group B.Conclusion:The therapeutic efficacy of valsartan accompanied with metoprolol in the patients with congestive heart failure(CHF) is satisfactory. There are few side effects.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective:To evaluate the therapeutic efficacy of valsartan accompanied with metoprolol in the patients with congestive heart failure(CHF).Methods: 96 patients with CHF were randomly divided into group A ( n =46) who had taken conventional treatment of digitalis and diuretics and group B ( n =50) who were given valsartan (40 to 160 mg·d -1 ) and metoprolol (12.5 to 100 mg·d -1 ) on the conventional therapy.The therapeutic period was 6 months. Results: After treatment,cardiac function (NYHA) improved; blood pressure,heart rate,cardiothoracic ratio,left ventricular diastolic ending diameter (LVDd) and left aurial diameter (LAd) all decreased; left ventricular ejectional fraction (LVEF) increased significantly( P 0.05 ) in group B comparing with those in group A. There were few side effects and patients' tolerance was perfect in Group B.Conclusion:The therapeutic efficacy of valsartan accompanied with metoprolol in the patients with congestive heart failure(CHF) is satisfactory. There are few side effects.
Key concepts: Metoprolol, Valsartan, Medicine, Heart failure, Ejection fraction, Cardiology, Internal medicine, Therapeutic effect